Copyright
©The Author(s) 2015.
World J Hepatol. Feb 27, 2015; 7(2): 139-149
Published online Feb 27, 2015. doi: 10.4254/wjh.v7.i2.139
Published online Feb 27, 2015. doi: 10.4254/wjh.v7.i2.139
Ref. | Year | n | Comparator | Cut-off-level | Sensitivity | Specificity | AUC |
Marrero et al[20] | 2009 | 836 total (419 HCC) | Liver cirrhosis | 20 ng/mL | 59% | 90% | 0.8 |
Mao et al[21] | 2010 | 4217 total (789 HCC) | Amongst others healthy controls, HBV carriers, liver cirrhosis | 35 ng/mL | 58.20% | 85.30% | |
Farinati et al[22] | 2006 | 1158 HCC | No control | 400 ng/mL | 18% | 0.59 | |
Lok et al[23] | 2010 | 39 HCC, 77 matched controls | Hepatitis C | 20 ng/mL | 61% | 81% | 0.79 |
Ref. | Year | Marker | n | Comparator | Cut-off-level | Sensitivity | Specifity | AUC |
Toyoda et al[31] | 2011 | hs-AFP-L3% | 666 | Chronic liver disease and AFP < 20 ng/mL | 5% | 41.50% | 85.10% | 0.707 |
Ertle et al[37] | 2013 | DCP | 586 | Chronic liver disease | 5 ng/mL | 45.80% | 95% | 0.87 |
Wan et al[24] | 2014 | Osteopontin | Meta-analysis (7 studies) | mixed | Pooled: 86% | Pooled: 86% | 0.92 | |
Hsia et al[35] | 2007 | IL-6 | 128 | Mixed, including chronic liver disease and healthy controls | 3 pg/mL | 46% | 95% | |
Mao et al[21] | 2010 | GP73 | 4217 | Mixed, including chronic liver disease and healthy controls | 8.5 rel. units | 74.60% | 97.40% | 0.94 |
Giannelli et al[36] | 2007 | SCCA | 961 | Liver cirrhosis | 3.8 ng/mL | 41.90% | 82.60% | 0.656 |
Ertle et al[37] | 2013 | AFP combined with DCP | 586 | Chronic liver disease | DCP 5 ng/mL AFP 10 ng/mL | 78% | 89.30% | 0.91 |
Johnson et al[40] | 2014 | GALAD-score | 670 | Chronic liver disease | 93% | 89% |
Ref. | Year | Correlation with | No. of genes in signature | AUC | P-value |
Nault et al[95] | 2013 | Disease-free survival after resection | 5 (tumor) | 0.8 | < 0.0001 |
Lim et al[96] | 2013 | Disease-free survival after resection | 25 (tumor) | 0.002 | |
Kurokawa et al[97] | 2004 | Tumor recurrence after resection | 20 (tumor) | 0.001 | |
Yoshioka et al[98] | 2009 | Tumor recurrence after resection | 172 (tumor) | < 0.0001 | |
Woo et al[99] | 2008 | Recurrence free survival | 628 (tumor) | < 0.01 |
- Citation: Schütte K, Schulz C, Link A, Malfertheiner P. Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol 2015; 7(2): 139-149
- URL: https://www.wjgnet.com/1948-5182/full/v7/i2/139.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i2.139